NANOSENS SPONSORS RESEARCH DONE IN THE KGI ARAN LAB:

ARAN BIOMEDICAL DEVICE LAB FOR DIAGNOSTICS AND THERAPEUTICS
Collaborating with fellow pioneers in the fields of aging and diagnostics and industry experts in graphene and drug delivery, the Aran Lab aims to forge novel platforms of analysis and diagnostics for future translational applications.
Research

Digital Diagnostic Platforms

The Aran Lab’s biosensor research aims to develop novel methods utilizing Cardea Bio's graphene-based field effect transistor biosensors to identify and capture target biological molecules for future clinical and industry use. 

Aging

Advancements in modern medicine have greatly extended human life expectancy. However, the onset of age-associated conditions is becoming an increasingly pressing issue. New and innovative solutions are needed to improve the quality of life as our population ages. The Aran Lab aims to further study the intricacies of aging through the development of novel analysis and therapeutic platforms.

Drug Delivery

The Aran Lab aims to characterize regional differences in healthy and diseased tissue and associated drug absorption. Our research works towards developing novel biosensor and microfluidics tools to better understand drug delivery and tissue parameters and developing an optimized targeted drug delivery platform to better provide therapeutics. 
Dr. Kiana Aran, Principal Investigator
Dr. Aran received her Ph.D. in Biomedical Engineering at the Rutgers University in 2012. She then continued her postdoctoral studies in bio-engineering at the University of California Berkeley. She was a recipient of the National Institutes of Health (NIH) postdoctoral training fellowship at the Buck Institute for Age Research in 2015. She joined the Keck Graduate Institute (KGI) of Applied Life Sciences in 2017 as an Assistant Professor.